



CLINICAL AND  
LABORATORY  
STANDARDS  
INSTITUTE®

February 2009

# GP16-A3

## Urinalysis; Approved Guideline—Third Edition

This document addresses procedures for testing urine, including materials and equipment; macroscopic/physical evaluation; chemical analysis; and microscopic analysis.

A guideline for global application developed through the Clinical and Laboratory Standards Institute consensus process.

This is a preview. [Click here to purchase the full publication.](#)

# Clinical and Laboratory Standards Institute

*Setting the standard for quality in medical laboratory testing around the world.*

The Clinical and Laboratory Standards Institute (CLSI) is a not-for-profit membership organization that brings together the varied perspectives and expertise of the worldwide laboratory community for the advancement of a common cause: to foster excellence in laboratory medicine by developing and implementing medical laboratory standards and guidelines that help laboratories fulfill their responsibilities with efficiency, effectiveness, and global applicability.

## **Consensus Process**

Consensus—the substantial agreement by materially affected, competent, and interested parties—is core to the development of all CLSI documents. It does not always connote unanimous agreement, but does mean that the participants in the development of a consensus document have considered and resolved all relevant objections and accept the resulting agreement.

## **Commenting on Documents**

CLSI documents undergo periodic evaluation and modification to keep pace with advancements in technologies, procedures, methods, and protocols affecting the laboratory or health care.

CLSI's consensus process depends on experts who volunteer to serve as contributing authors and/or as participants in the reviewing and commenting process. At the end of each comment period, the committee that developed the document is obligated to review all comments, respond in writing to all substantive comments, and revise the draft document as appropriate.

Comments on published CLSI documents are equally essential, and may be submitted by anyone, at any time, on any document. All comments are managed according to the consensus process by a committee of experts.

## **Appeals Process**

When it is believed that an objection has not been adequately considered and responded to, the process for appeals, documented in the CLSI Standards Development Policies and Processes, is followed.

All comments and responses submitted on draft and published documents are retained on file at CLSI and are available upon request.

## **Get Involved—Volunteer!**

Do you use CLSI documents in your workplace? Do you see room for improvement? Would you like to get involved in the revision process? Or maybe you see a need to develop a new document for an emerging technology? CLSI wants to hear from you. We are always looking for volunteers. By donating your time and talents to improve the standards that affect your own work, you will play an active role in improving public health across the globe.

For additional information on committee participation or to submit comments, contact CLSI.

Clinical and Laboratory Standards Institute  
950 West Valley Road, Suite 2500  
Wayne, PA 19087 USA  
P: +1.610.688.0100  
F: +1.610.688.0700  
[www.clsi.org](http://www.clsi.org)  
[standard@clsi.org](mailto:standard@clsi.org)

This is a preview. [Click here to purchase the full publication.](#)

ISBN 1-56238-687-5  
ISSN 0273-3099

GP16-A3  
Vol. 29 No. 4  
Replaces GP16-A2  
Vol. 21 No. 19

---

## Urinalysis; Approved Guideline—Third Edition

Volume 29 Number 4

Albert Rabinovitch, MD, PhD  
Lena Arzoumanian, MS, MT(CLS, NCA)  
Krista M. Curcio, MT(ASCP)  
Bill Dougherty  
Abdel-Baset Halim, PharmD, PhD

### Abstract

Clinical and Laboratory Standards Institute document GP16-A3—*Urinalysis; Approved Guideline—Third Edition* is written for laboratory and nonlaboratory personnel responsible for the collection, transport, and analysis of urine specimens. The guideline addresses macroscopic evaluation, chemical analysis, and microscopic examination of urine. The necessary materials and equipment used in the process are considered.

Clinical and Laboratory Standards Institute (CLSI). *Urinalysis; Approved Guideline—Third Edition*. CLSI document GP16-A3 (ISBN 1-56238-687-5). Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087 USA, 2009.

The Clinical and Laboratory Standards Institute consensus process, which is the mechanism for moving a document through two or more levels of review by the health care community, is an ongoing process. Users should expect revised editions of any given document. Because rapid changes in technology may affect the procedures, methods, and protocols in a standard or guideline, users should replace outdated editions with the current editions of CLSI documents. Current editions are listed in the CLSI catalog and posted on our website at [www.clsi.org](http://www.clsi.org). If your organization is not a member and would like to become one, and to request a copy of the catalog, contact us at: Telephone: 610.688.0100; Fax: 610.688.0700; E-Mail: [customerservice@clsi.org](mailto:customerservice@clsi.org); Website: [www.clsi.org](http://www.clsi.org).



This is a preview. [Click here to purchase the full publication.](#)

Copyright ©2009 Clinical and Laboratory Standards Institute. Except as stated below, any reproduction of content from a CLSI copyrighted standard, guideline, companion product, or other material requires express written consent from CLSI. All rights reserved. Interested parties may send permission requests to [permissions@clsi.org](mailto:permissions@clsi.org).

CLSI hereby grants permission to each individual member or purchaser to make a single reproduction of this publication for use in its laboratory procedure manual at a single site. To request permission to use this publication in any other manner, e-mail [permissions@clsi.org](mailto:permissions@clsi.org).

### **Suggested Citation**

CLSI. *Urinalysis; Approved Guideline—Third Edition*. CLSI document GP16-A3. Wayne, PA: Clinical and Laboratory Standards Institute; 2009.

### **Previous Editions:**

July 1991, December 1992, December 1995, November 2001

### **Reaffirmed:**

September 2016

ISBN 1-56238-687-5  
ISSN 0273-3099

## Committee Membership

### Area Committee on Quality System and Laboratory Practices

**Sheila M. Woodcock, MBA,**  
**FCSMLS(D)**  
**Chairholder**  
**QSE Consulting**  
**Rose Bay, Nova Scotia, Canada**

**Albert Rabinovitch, MD, PhD**  
**Co-Vice-Chairholder**  
**NovoMetrics, Inc.**  
**Mountain View, California**

**Carl Mottram, BA, RRT, RPFT,**  
**FAARC**  
**Co-Vice-Chairholder**  
**Mayo Clinic**  
**Rochester, Minnesota**

Eric Arendash, MT(ASCP)  
 Centers for Medicare & Medicaid  
 Services  
 Philadelphia, Pennsylvania

Lucia M. Berte, MA, MT(ASCP)SBB,  
 DLM  
 Quality Systems Consultant  
 Broomfield, Colorado

Theresa Billups, MBA, MT(ASCP),  
 DLM  
 Remel, Inc.  
 Lake Charles, Louisiana

Margaret M. Grimes, MD  
 Virginia Commonwealth University  
 Richmond, Virginia

Devery Howerton, PhD  
 Centers for Disease Control and  
 Prevention  
 Atlanta, Georgia

Peter L. Minetti, CQA, CQE,  
 CQMgr(ASQ)  
 Fujirebio Diagnostics, Inc.  
 Malvern, Pennsylvania

Bruce D. Tually, BAppSc, MAppSc  
 Hunter Area Pathology Service  
 New South Wales, Australia

#### Advisors

Kay M. Creed  
 St. Mary's Hospital  
 Richmond, Virginia

Dennis J. Ernst, MT(ASCP)  
 Center for Phlebotomy Education  
 Ramsey, Indiana

Steven I. Gutman, MD, MBA  
 FDA Ctr. for Devices/Rad. Health  
 Rockville, Maryland

Stephen J. Sarewitz, MD  
 Valley Medical Center  
 Renton, Washington

Jennifer Schiffgens, MBA, MT(ASCP)  
 California Pacific Medical Center  
 San Francisco, California

Daniel W. Tholen, MS  
 Dan Tholen Statistical Consulting  
 Traverse City, Michigan

#### Staff

Clinical and Laboratory Standards  
 Institute  
 Wayne, Pennsylvania

Lois M. Schmidt, DA  
*Vice President, Standards  
 Development and Marketing*

Jennifer K. McGeary, MT(ASCP),  
 MSHA  
*Staff Liaison*

Melissa A. Lewis  
*Editor*

### Acknowledgment

CLSI and the Area Committee on Quality Systems and Laboratory Practices gratefully acknowledge the experts listed below for their help in preparing the approved-level, third edition of this guideline.

Albert Rabinovitch, MD, PhD; NovoMetrics, Inc.  
 Lena Arzoumanian, MS, MT(CLS, NCA); BD Diagnostics, Preanalytical Systems  
 Krista M. Curcio, MT(ASCP); Sysmex America, Inc.  
 Bill Dougherty; International Remote Imaging Systems  
 Abdel-Baset Halim, PharmD, PhD; Daiichi Sankyo Pharma Development



## Contents

Abstract.....	i
Committee Membership.....	iii
Foreword.....	vii
1 Scope.....	1
2 Introduction.....	1
3 Standard Precautions.....	2
4 Terminology.....	2
4.1 Definitions .....	2
4.2 Abbreviations/Acronyms .....	4
5 Preexamination Activities.....	4
5.1 Overview.....	4
5.2 Types of Urine Specimens.....	4
5.3 Instructing the Patient .....	5
5.4 Specimen Collection .....	5
5.5 Specimens From Infants and Small Children .....	7
5.6 Collection Containers .....	8
5.7 Specimen Transport and Storage .....	9
5.8 Acceptability of Specimens and Quality Assurance .....	10
6 Testing Materials and Equipment .....	11
6.1 Materials .....	11
6.2 Equipment.....	12
6.3 Quality Control .....	13
7 Macroscopic/Physical Urinalysis.....	14
7.1 Specimen Acceptability .....	14
7.2 Color, Clarity, and Odor .....	15
7.3 Urine Concentration (Specific Gravity).....	15
8 Chemical Urinalysis – Manual.....	16
8.1 Precautions for Reagent Strip Use .....	16
8.2 Use of Reagent Strips .....	16
8.3 Confirmatory Tests .....	17
9 Microscopic Urinalysis – Manual.....	17
9.1 Manual Microscopy .....	18
9.2 Identification of Microscopic Entities .....	20
9.3 Quality Assurance of the Microscopic Examination .....	21
10 Automated Urinalysis .....	21
10.1 Automated Methods.....	22
11 Quality Assurance.....	24
11.1 Introduction and Purpose .....	24